Statistical methods in women's health & pregnancy trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
ANCOVA
Non-inferiority trial design
Mixed-effects model
Hazard ratio
Multiple imputation / missing data
Cochran-Mantel-Haenszel test
Odds ratio
Logistic regression
All women's health & pregnancy trials
490 results
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer: primary endpoint…
- A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria: Complete Statistical AnalysisIndependent statistical analysis of A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study in Participants With Diabetic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study in Participants With Diabetic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01113801).
- A Study of Abemaciclib in Indian Women With Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Abemaciclib in Indian Women With Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1): Complete Statistical AnalysisIndependent statistical analysis of A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA): Complete Statistical AnalysisIndependent statistical analysis of A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA): primary endpoint results, effect estimate…
- A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF): Complete Statistical AnalysisIndependent statistical analysis of A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF): primary endpoint results, effect estimate with confidence interval,…
- A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation: Complete Statistical AnalysisIndependent statistical analysis of A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator’s Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC): Complete Statistical AnalysisIndependent statistical analysis of A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for…
- A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia: Complete Statistical AnalysisIndependent statistical analysis of A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of Breastfeeding in Buprenorphine Maintained Women: Complete Statistical AnalysisIndependent statistical analysis of A Study of Breastfeeding in Buprenorphine Maintained Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01806389).
- A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.: Complete Statistical AnalysisIndependent statistical analysis of A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy: Complete Statistical AnalysisIndependent statistical analysis of A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy: primary endpoint results, effect estimate with confidence interval,…
- A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer: primary…
- A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive…
- A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: primary endpoint results, effect…
- A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.: Complete Statistical AnalysisIndependent statistical analysis of A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.: primary endpoint results, effect…
- A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of LY2541546 in Healthy Postmenopausal Women: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY2541546 in Healthy Postmenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01742078).
- A Study of LY2928057 in Hemodialysis Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY2928057 in Hemodialysis Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01991483).
- A Study of LY3113593 in Participants With Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3113593 in Participants With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02604160).
- A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011): Complete Statistical AnalysisIndependent statistical analysis of A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002): Complete Statistical AnalysisIndependent statistical analysis of A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of MORAb-202 Versus Investigator’s Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: primary endpoint results, effect estimate…
- A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II): Complete Statistical AnalysisIndependent statistical analysis of A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II): primary endpoint results, effect estimate with confidence…
- A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Study of Pertuzumab in Participants With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Pertuzumab in Participants With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02491892).
- A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems: Complete Statistical AnalysisIndependent statistical analysis of A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study Of PF-06664178 In Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of A Study Of PF-06664178 In Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02122146).
- A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies: Complete Statistical AnalysisIndependent statistical analysis of A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer: primary endpoint results, effect…
- A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B): Complete Statistical AnalysisIndependent statistical analysis of A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B): primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of TAS-120 in Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of TAS-120 in Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04024436).
- A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.: Complete Statistical AnalysisIndependent statistical analysis of A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary…
- A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding: Complete Statistical AnalysisIndependent statistical analysis of A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…